Lip G Y H, Pearce L A, Chin B S P, Conway D S G, Hart R G
Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK.
Heart. 2005 Jun;91(6):759-63. doi: 10.1136/hrt.2004.036160.
To examine further the relations of plasma von Willebrand factor (vWf, an index of endothelial damage and dysfunction) and soluble P-selectin (sP-sel, an index of platelet activation) concentrations to the presence and onset of clinical congestive heart failure (CHF) and the degree of left ventricular (LV) dysfunction in patients taking part in the SPAF (stroke prevention in atrial fibrillation) study.
Plasma concentrations of vWf and sP-sel were measured by enzyme linked immunosorbent assay (ELISA) in 1321 participants in the SPAF III study and related to the presence and onset of clinical CHF, as well as echocardiographic findings. Of the 1321 patients with atrial fibrillation (AF), 331 (25%) had a documented history of clinical heart failure, of which 168 cases were related to a new or recurrent episode of acute decompensated heart failure occurring within the preceding three months.
Mean plasma vWf was higher among patients with AF and CHF (154 (29) v 144 (31) IU/dl, p < 0.001), particularly those with acute or recent decompensated symptoms. Patients with severe LV dysfunction on two dimensional echocardiography and low fractional shortening also had significantly higher vWf concentrations than those with no LV dysfunction. CHF patients with clinical features--with (156 (28) IU/dl) and without (152 (31) IU/dl) LV dysfunction--also had higher mean vWf concentrations than patients with asymptomatic LV dysfunction (146 (31) IU/dl, p < 0.001). The presence of mitral regurgitation in CHF was associated with lower vWf concentrations. Plasma sP-sel concentrations were not affected by presence, onset, or severity of heart failure.
CHF may contribute to hypercoagulability and thrombotic risk in AF through increased endothelial damage and dysfunction. Patients with acute or recent decompensated features have the highest degree of endothelial damage and dysfunction. The presence of CHF clinical features was an important determinant of plasma vWf concentrations.
进一步研究参与SPAF(心房颤动卒中预防)研究的患者血浆血管性血友病因子(vWf,内皮损伤和功能障碍指标)及可溶性P选择素(sP-sel,血小板活化指标)浓度与临床充血性心力衰竭(CHF)的存在及发作以及左心室(LV)功能障碍程度之间的关系。
采用酶联免疫吸附测定(ELISA)法检测1321例参与SPAF III研究患者的血浆vWf和sP-sel浓度,并将其与临床CHF的存在及发作以及超声心动图检查结果相关联。在1321例心房颤动(AF)患者中,331例(25%)有临床心力衰竭的记录病史,其中168例与前三个月内发生的新的或复发的急性失代偿性心力衰竭发作有关。
AF合并CHF患者的平均血浆vWf水平更高(154(29)对144(31)IU/dl,p<0.001),尤其是那些有急性或近期失代偿症状的患者。二维超声心动图显示严重LV功能障碍且缩短分数低的患者的vWf浓度也显著高于无LV功能障碍的患者。有临床特征的CHF患者——有LV功能障碍(156(28)IU/dl)和无LV功能障碍(152(31)IU/dl)——的平均vWf浓度也高于无症状LV功能障碍患者(146(31)IU/dl,p<0.001)。CHF中二尖瓣反流的存在与较低的vWf浓度相关。血浆sP-sel浓度不受心力衰竭的存在、发作或严重程度的影响。
CHF可能通过增加内皮损伤和功能障碍导致AF中的高凝状态和血栓形成风险。有急性或近期失代偿特征的患者内皮损伤和功能障碍程度最高。CHF临床特征的存在是血浆vWf浓度的重要决定因素。